|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Net loss | |||||
| (Income) loss from discontinued operations | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Depreciation and amortization | |||||
| Amortization of debt discount | |||||
| Gain from sale of discontinued operation | |||||
| Share-based compensation | |||||
| Other noncash changes | |||||
| Loss from intangible impairment | |||||
| ROU assets, net | |||||
| Loss from intangible impairment | |||||
| Non-cash share-based compensation | |||||
| Change in FV of derivative liability | |||||
| Loss on extinguishment of debt | |||||
| Changes in working capital items: | |||||
| Accounts receivable, net | |||||
| Inventory, net | |||||
| Prepaid expenses and other current assets | |||||
| Deposits | |||||
| Accounts payable and accrued expenses | |||||
| Accrued interest payable | |||||
| Net cash used in operating activities - continuing operations | |||||
| Net cash used in operating activities - discontinued operations | |||||
| Cash flows from investing activities - continuing operations | |||||
| Capital expenditures | |||||
| Net cash used in investing activities - continuing operations | |||||
| Net cash used in investing activities - discontinued operations | |||||
| Cash flows from financing activities - continuing operations: | |||||
| Proceeds from issuance of Common stock | |||||
| Cash advance (repayment) from shareholder | |||||
| Cash advance (repayment) from related party | |||||
| Proceeds from issuance of debt | |||||
| Proceeds from sale of preferred stock | |||||
| Principal repayment of debt | |||||
| Net cash provided by financing activities - continuing operations | |||||
| Net cash provided by financing activities - discontinued operations | |||||
| Operating cash flows | |||||
| Net cash provided by (used in) discontinued operations | |||||
| Net cash effect of exchange rates on cash | |||||
| Net change in cash and cash equivalents | |||||
| Cash and Cash Equivalents, end of year | |||||
| Cash and cash equivalents, beginning of year | |||||
| Cash and cash equivalents, end of period | |||||
| Supplemental Disclosure of Cash Flow Information: | |||||
| Cash paid for Interest | |||||
| Convertible notes payable and accrued interest converted to common stock (452,914 shares) | |||||
| Convertible notes payable and accrued interest converted to common stock (458,500 shares) | |||||
| Notes payable and accrued interest converted to Common Stock (944,685 shares in 2025 & 171,536 shares in 2024,) | |||||
| Non-cash debt discount in the form of issuance of equity instruments in conjunction with convertible notes | |||||
| Series-B Convertible Preferred Stock Issued 126,710 shares exchanged for notes payable and accrued interest | |||||
Loading...